PedAM
Pediatric Disease Annotations & Medicines
| Disease | pleural effusion disorder |
| Phenotype | C0007131|non-small cell lung cancer |
| Sentences | 9 |
| PubMedID- 20207133 | Purpose: to investigate the feasibility, pharmacokinetics, efficacy and toxicity of intrapleural paclitaxel liposome injection in non-small cell lung cancer (nsclc) patients with malignant pleural effusions. |
| PubMedID- 21625182 | Predictive value of f-18 fdg pet/ct for malignant pleural effusion in non-small cell lung cancer patients. |
| PubMedID- 25999646 | Patients in this study are enrolled in a phase i clinical trial of hpph-mediated pdt for the treatment of non-small cell lung cancer with pleural effusion. |
| PubMedID- 23523589 | Background: apolipoprotein e (apoe) levels have been shown to be elevated in pleural effusion of patients with non-small cell lung cancer (nsclc). |
| PubMedID- 24758329 | Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer. |
| PubMedID- 20819493 | Objective: to compare the therapeutic effects of pleural perfusion of ndp and cddp in non-small cell lung cancer (nsclc) patients with malignant pleural effusion, their quality of life and toxic side effects. |
| PubMedID- 23898708 | However, this condition is sometimes discovered, with or without a small amount of pleural effusion, at thoracotomy in patients with resectable non-small cell lung cancer. |
| PubMedID- 26005243 | The patients studied here are enrolled in a phase i clinical trial of hpph-mediated pdt for the treatment of non-small cell lung cancer with pleural effusion. |
| PubMedID- 23925664 | Vascular endothelial growth factor (vegf) is involved in non-small cell lung cancer (nsclc) with malignant pleural effusion (mpe), but little is known regarding the efficacy of bevacizumab (bev) with carboplatin-paclitaxel (cp) for nsclc with mpe. |
Page: 1